HIV since at least the advent of antiretroviral therapy. In a report on “Overcoming disruption, transforming the AIDS response,” released last week ahead of World AIDS Day on Dec. 1, the Joint United ...

Ascletis Pharma Inc. has selected ASC-37 oral tablets as a clinical development candidate for the treatment of obesity. The company expects to submit an IND application to the FDA in the second ...

Pancreatic cancer is among the most aggressive cancer types, with survival rates being very low and current treatment being ...

Inhibiting transient receptor potential melastatin 2 (TRPM2) may mitigate injury arising from ischemic stroke. Researchers at ...

Kedrion SpA’s investigational plasma-derived treatment for congenital aceruloplasminemia has been awarded European orphan ...

Raqualia Pharma Inc.’s Fimecs Inc. subsidiary has agreed with Astellas Pharma Inc. to add two new targets under their ongoing ...

Researchers from Stanford University have reported that inhibiting the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) ...

The Sept. 4, 2015, at-risk launch of Sandoz Inc.’s Zarxio as the first biosimilar to hit the U.S. market came several months ...

Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has ...

CSPC Pharmaceutical Group Ltd. has gained clinical trial clearance from China’s National Medical Products Administration ...

In an effort to develop more effective estrogen receptor α (ERα) inhibitors, researchers at Nanjing University of Chinese ...

Myrio Therapeutics Pty Ltd. has been able to accomplish something no other company has yet been able to crack: to develop ...